HR Execs on the Move

Global Blood Therapeutics

www.gbt.com

 
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.gbt.com
  • 171 Oyster Point Boulevard Suite 300
    South San Francisco, CA USA 94080
  • Phone: 650.741.7700

Executives

Name Title Contact Details
Robert Gatmaitan
Head of Global Total Rewards, People Analytics, and HR Operations Profile
Carrie Krehlik
Chief Human Resources Officer Profile

Similar Companies

Elusys Therapeutics

Elusys Therapeutics is a Pine Brook, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EYELA Tokyo Rikakikai Co

EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Millennium Pharmaceuticals Inc

Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering

CARsgen

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Bioporto

BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.